Boston Scientific announced it has received U.S. Food and Drug Administration (FDA) approval for the Vercise Neural Navigator 5 Software, which when used as part of the Vercise Genus Deep Brain Stimulation (DBS) Systems, can provide clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson’s disease or essential tremor.
The Vercise Neural Navigator 5 Software, with STIMVIEW XT Technology, is the latest addition to the fully integrated portfolio of image guided programming solutions for Boston Scientific DBS Systems. Developed in collaboration with Brainlab AG, a leading software-driven medical technology company, these tools have demonstrated a reduction in programming time by 56% and provide real-time visualization and stimulation of each person’s unique brain anatomy.
The Vercise Neural Navigator 5 Software includes an enhanced user interface that displays patient data in a simplified format and gives clinicians access to advanced settings for increased therapy delivery. The software is designed to enable more flexibility to better manage the evolving needs of individual patients at any stage of their condition.
